StockVS

BNB Plus Corp. (BNBX) Stock Analysis

Financial Services

BNB Plus Corp.

$0.40

+$0.02 (+5.40%)

Last Updated: May 26, 2026

Price History

Analysis

Company Overview

BNB Plus Corp. operates within the financial services sector, specifically focusing on the asset management industry where it provides digital asset treasury services alongside real-time data tracking of treasury performance and market indicators. Through its subsidiaries, the entity also engages in the development and commercialization of technologies designed to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid. The company maintains a modest operational scale with a current market capitalization of $3.76M, annual revenue of $1.83M, and an employee base of 26 individuals. These valuation and revenue figures indicate that BNB Plus Corp. is a small-cap entity with limited revenue generation relative to its market presence, suggesting a niche operational footprint rather than broad market dominance. The combination of digital asset services and biotechnology technology development positions the firm at the intersection of financial services and specialized scientific innovation, though the small market cap implies significant volatility and limited liquidity compared to larger peers.

Financial Health

The company reported a revenue of $1.83M for the trailing twelve months, yet this generated a net income of $-70,157,456 and an EBITDA of $-28,339,856. The substantial gap between the positive revenue of $1.83M and the deeply negative net income reveals a highly aggressive cost structure or significant one-time charges that erode profitability despite top-line activity. Free cash flow stands at $-17,404,216, indicating that the company is currently burning cash and lacks the immediate financial flexibility to fund operations without external capital injections. The gross margin is 29.9%, which suggests that the company retains a nearly 30% portion of sales after direct costs, while the operating margin of -3248.8% and profit margin of 0.0% highlight severe operational inefficiencies or extraordinary expenses that prevent the company from converting revenue into operating profit. On the balance sheet, the company holds $2.45M in cash against $48,861 in debt, resulting in a debt-to-equity ratio of 0.27, which points to a conservative leverage position where equity significantly outweighs liabilities. The current ratio of 2.32 indicates that the company possesses 2.32 times the current assets necessary to cover its short-term obligations, suggesting adequate short-term liquidity despite the cash burn. Return on Equity is -199.1% and Return on Assets is -98.0%, metrics that reveal management is currently destroying shareholder value and failing to generate returns on the capital deployed to run the business.

Valuation Assessment

The trailing P/E ratio is 0.00 while the forward P/E is N/A, a disparity that implies the company has no earnings to value against current stock price and that future earnings estimates are unavailable or non-existent for valuation purposes. The price-to-book ratio is 0.17, indicating that the market values the company at less than one-fifth of its book value, which suggests significant market skepticism regarding the quality of its assets or the realization of its intangible technology value. Alternative valuation metrics include a price-to-sales ratio of 2.05 and an EV/EBITDA of -0.04, figures that suggest the stock is trading at a premium relative to sales despite being unprofitable, a common characteristic of speculative growth or turnaround plays that investors may be pricing for future recovery. The stock has experienced extreme volatility within its trading range, with a 52-week high of $35.85 and a 52-week low of $0.61. Based on the provided data, the current trading environment reflects high uncertainty, though without a specific current price listed in the facts, the range demonstrates a massive potential swing from lows near 0.61 to highs near 35.85. The beta value is 0.69, which indicates that the stock is less volatile than the broader market, moving at roughly 31% less intensity than the benchmark, yet this lower volatility is often observed in small-cap stocks that are frequently illiquid.

Growth & Income

Revenue growth year-over-year is -35.0%, while earnings growth is N/A due to the lack of comparable prior earnings data, making it impossible to determine if earnings are growing faster or slower than revenue at this specific point in time. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the entity retains all its earnings or losses rather than distributing income to shareholders. As a non-dividend payer, the company theoretically reinvests any available resources or seeks to grow through operations, though the negative free cash flow limits the ability to fund internal expansion without external financing. The overall growth and income profile is characterized by significant revenue contraction and an absence of income distribution, reflecting a firm in a stage of development or distress where capital preservation is likely the primary focus rather than income generation or expansion.

Peer Comparison

BNB Plus Corp. (BNBX) operates in the Asset Management industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BNB Plus Corp. BNBX $2.88M 0.0
BlackRock, Inc. BLK $167.25B 27.1
Blackstone Inc. BX $144.37B 30.3
Brookfield Corporation BN.TO $142.06B 89.6

The Asset Management industry average P/E ratio is 28.6x. BNB Plus Corp. trades at a P/E of 0.0.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About BNB Plus Corp.

BNB Plus Corp. provides digital asset treasury services. The company offers real-time data tracking of treasury performance and market indicators. The company, through its subsidiaries, also develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the Americas, Europe, Asia, and internationally. The company engages in the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and nucleic acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP, and LineaIVT, as well as the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. BNB Plus Corp. was formerly known as Applied DNA Sciences, Inc. and changed its name to BNB Plus Corp. in November 2025. The company was founded in 1983 and is based in Stony Brook, New York.

Visit website →

Key Statistics

Market Cap
$2.88M
P/E Ratio
0.00
52-Week High
$8.25
52-Week Low
$0.37
Avg Volume
874.65K
Beta
0.56

Data provided by Yahoo Finance via yfinance. Updated daily.

Company Info

Exchange
NASDAQ
Country
United States
Employees
26